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Abstract
Background: Available treatments for uncomplicated hepatic cystic echinococcosis (CE) include surgery, medical
therapy with albendazole (ABZ), percutaneous interventions and the watch-and-wait (WW) approach. Current
guidelines indicate that patients with hepatic CE should be assigned to each option based on cyst stage and size,
and patient characteristics. However, treatment indications for transitional CE3b cysts are still uncertain. These cysts
are the least responsive to non-surgical treatment and often present as indolent, asymptomatic lesions that may
not warrant surgery unless complicated. Evidence supporting indications for treatment of this stage is lacking.
In the attempt to fill this gap before the implementation of randomized clinical trials, we compared the clinical
behavior of single hepatic CE3b cysts in 60 patients followed at the WHO Collaborating Centre for Cystic
Echinococcosis of the University of Pavia.
Methods: We analyzed retrospectively data of 60 patients with hepatic CE3b cysts seen at our clinic over 27 years,
who either received ABZ or were monitored with WW. Univariate and multivariate analysis were performed to
investigate the effect on outcome (inactivation or relapse) of variables such as age, sex, origin, treatment, cyst size
and presence of other echinococcal hepatic cysts using a multiple failure Cox proportional hazard model.
Results: ABZ treatment was positively associated with inactivation (p < 0.001), but this was not permanent, and no
association was found between therapeutic approach and relapse (p = 0.091). No difference was found in the rate
of complications between groups.
Conclusions: In conclusion, our study shows that ABZ treatment induces temporary inactivation of CE3b cysts,
while during WW cysts remain stable over time. As the rate of adverse events during periods of ABZ treatment and
WW did not differ significantly in the follow-up period considered in this study (median 43 months, IQR 10.7-141.5),
expectant management might represent a valuable option for asymptomatic CE3b cysts when strict indication for
surgery is absent and patients comply with regular long-term follow-up.
Background
Cystic Echinococcosis (CE), caused by the zoonotic tape-
worm Echinococcus granulosus, is a serious health prob-
lem in many regions of the world, but is among the most
neglected parasitic diseases [1]. The liver is the most
frequent location of echinococcal cysts (70% of cases),
with a highly variable clinical presentation, ranging from
asymptomatic to life-threatening manifestations [2,3]. The
current management of CE is based on quality of evidence
III (evidence from opinions of respected authorities, based
on clinical experience, descriptive studies, or reports of
committees) with B-D recommendation strength (moder-
ate to poor evidence to support recommendation). This
situation results from the lack of longitudinal controlled
studies, which is partly due to (1) the chronicity of the
disease which requires years-long follow-up to evaluate
the effectiveness of an intervention, (2) the relatively
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low number of patients presenting with clinically homo-
geneous conditions, even in referral centres in endemic
countries, such our WHO collaborative centre in Italy,
and (3) to the difficulty in comparing results from dif-
ferent studies [4].
The classification and clinical management of CE have
been only recently addressed in a more harmonized man-
ner [4]. The diagnosis of CE is based mainly on imaging
methods and serology, with the latter having a comple-
mentary role [4]. Ultrasonography (US) is the mainstay of
diagnosis of abdominal CE [5]. The WHO Informal
Working Group on Echinococcosis (WHO-IWGE) classi-
fication, introduced in 2003, describes 5 CE stages based
on US features (Figure 1): CE1 and CE2 are active cysts,
CE3 are transitional, and CE4 and CE5 are inactive cysts
[6]. Observations on the response to non-surgical therapy
and metabolic profiles using magnetic resonance spectros-
copy have shown that this classification largely reflects the
biological and metabolic activity of the cysts [7,8]. Accord-
ingly, CE3 cysts have been further divided into CE3a,
which are equally likely to be active or inactive, and CE3b,
which are biologically active [7].
Cyst staging and the experience gathered in a number
of referral centres allowed for a more rational allocation
of uncomplicated cysts to the different available treatments
(surgery, medical therapy, percutaneous interventions
or “watch-and-wait” approach) (Figure 1) [4]. Treatment
with albendazole (ABZ) is recommended to be adminis-
tered continuously in courses of 3 to 6 months or lon-
ger, depending on cyst stage and patient characteristics
[4,13-15]. The “watch and wait” approach (WW) con-
sists of regular US follow-up without interventions on
the cyst in the absence of reactivation or complications.
In our centre, this approach is currently the choice for
uncomplicated inactive CE4 and CE5 cysts [4,6,16-18].
CE3b cysts are poorly responsive to non-surgical treat-
ment [8,11] and often present as indolent, asymptom-
atic or paucisymptomatic lesions that may not warrant
surgery unless complicated. There is a lack of evidence
supporting indications for treatment for these cyst
stages. Often, after an attempted treatment with ABZ,
which almost inevitably results in failure (i.e. relapse oc-
curring shortly after inactivation obtained at the end of
treatment) [19], in our centre CE3b cysts are allocated
to the WW approach, if the patient agrees to comply
with regular follow-up.
In this study we compared the behaviour of and occur-
rence of complications in CE3b cysts treated with ABZ
with those managed with the WW approach, in a cohort
of patients seen in our centre over 27 years.
Figure 1 Schematic representation of the natural history of hepatic CE and suggested treatments. Black arrows indicate proposed cyst
natural history based on clinical observation (Brunetti E., unpublished). Solid black arrows indicate natural evolution toward inactivation; black
dashed arrows indicate evolution of therapy-unresponsive chronic stages. US images: cyst ultrasound classifications according to WHO-IWGE
(in bold) and Gharbi [9]. As WHO-IWGE stage CE3b had not been explicitly described by Gharbi it is generally considered type III [10]. Gray boxes:
suggested stage-specific approach to uncomplicated hepatic CE [4,11,12]. ABZ = Albendazole; PAIR = Puncture, Aspiration, Injection of scolecidal
agent, Re-aspiration; PC = Permanent Catheterization.




All patients gave their written informed consent to data
treatment and the study was approved by the Ethics
Committee of IRCCS San Matteo Hospital Foundation,
Pavia, Italy.
Data extraction and inclusion criteria
This is a retrospective, comparative study of medical
treatment vs WW of patients with hepatic CE3b cysts.
Clinical and demographic data of CE patients seen in
our WHO Collaborating Centre for Cystic Echinococcosis
from January 1985 through December 2012 were extracted
from the Echinococcosis Database (FileMaker Inc., Santa
Clara, CA, USA) and double-checked in the paper-based
archive. Only patients with at least one hepatic CE3b cyst
on first consultation and with a minimum of two follow-up
visits were included in the analysis. In the case of patients
diagnosed with multiple CE3b cysts, the most active cyst,
i.e. the cyst with higher relapsing rate, was considered in the
analysis. To reduce possible confounding factors, patients
harbouring a CE3b cyst together with CE1, CE2, or CE3a
cysts were excluded from the study, while those harboring
a CE3b cyst together with one or more CE4 or CE5 cysts
were included. Follow-up was defined as more than one
consultation independent of time between visits. Data ex-
tracted included patient’s demographic data, geographical
origin, cyst number, size, stage and location, time to
inactivation (i.e. evolution from CE3b to inactive CE4-
CE5 stage), time to relapse (i.e. reappearance of daugh-
ter vesicles in the cysts that had reached the inactive
stage CE4 or CE5), treatments, and complications.
Patients who had not had a consultation during the last
two years of the studied period (i.e. in 2011 and 2012) or
longer, were contacted by telephone to inquire about their
condition and reason for not coming to follow-up visits.
Data collected by telephone were not included in the stat-
istical analysis.
Cysts characteristics and classification of follow-up events
Patients were evaluated by US at each follow-up visit by
an Infectious Diseases clinician with long-standing experi-
ence in clinical ultrasound (EB). For records post-2003,
cysts were staged according to the standardized WHO-
IWGE ultrasound classification [6]. Cysts diagnosed prior
to this date were classified according to Gharbi classifica-
tion [9]. In these cases, Type III cysts were double checked
in the photo archive and those considered as CE3b stage
were included in the analysis (Figure 1). Cyst size at first
consultation and before any complication event was classi-
fied as: S <5 cm, M= 5–10 cm, L >10 cm, based on the
largest diameter and according to the WHO-IWGE classi-
fication [6].
The majority (58%) of CE3b cysts seen in our centre
were treated with several courses of ABZ followed by at
least 24 months of WW. This length of observation in the
absence of treatment (≥24 months) was considered long
enough to avoid confounding effects (“carry-over effect”)
of the ABZ treatment on the outcome due to the natural
history of the cyst during the WW period [20,21]. Patients
were therefore grouped as “ABZ only”, “ABZ/WW”, and
“WW only” as schematized in Figure 2.
Complications were divided into mild, severe and lethal.
Complications considered unrelated with ABZ intake were
as follows. Mild: abdominal pain (experienced during pe-
riods of WW), gastrointestinal symptoms such as nausea
and vomiting (experienced during periods of WW), and
allergic cutaneous manifestations; severe: cyst rupture, de-
velopment of biliary fistula, infection of the cyst cavity,
secondary dissemination, and anaphylactic shock. Adverse
events considered likely to be associated with ABZ treat-
ment were as follows. Mild: alopecia, self-limiting, up to
5-fold increase in liver enzymes, rash, abdominal pain (ex-
perienced during ABZ intake), gastrointestinal symptoms
such as nausea and vomiting (experienced during ABZ in-
take), and headache; severe: bone marrow suppression
and liver damage [22,23]. To our knowledge, only one
Figure 2 Patients grouped by clinical management.
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case of death related to ABZ treatment has been reported
in the literature [24].
Statistical analysis
Univariate and multivariate analysis were performed to
investigate the effect on outcome (inactivation or relapse)
of variables such as age, sex, origin, treatment, cyst size
and presence of other echinococcal hepatic cysts using a
multiple failure Cox proportional hazard model. Age, treat-
ment, cyst size and presence of other cysts were treated as
time-dependent covariates. Periods of ABZ treatment and
periods of WW follow-up (treatments groups, as illustrated
in Figure 2) were considered separately, but taking into ac-
count that periods were clustered across subjects. For every
variable, robust standard errors were calculated to correct
for correlation between different treatment periods (ABZ
or WW) of the same subject. Thus, a patient could act as
his own control during different treatment periods (ABZ
or WW). In addition, comparability between groups was
also guaranteed by the use of a multivariate analysis.
Differences in cumulative time to inactivation and time
to relapse between treatment groups were investigated
using Kaplan-Meyer estimator. Incidence of complications
were calculated together with their 95% CI and compared
between treatment groups using an exact binomial test.
All analyses were performed using STATA software (Stata
Corporation, College Station, TX, USA). A p-value ≤0.05
was considered significant.
Results
Data from 60 patients, seen over 27 years (1985–2012)
in our centre and fulfilling the inclusion criteria, were ex-
tracted from the database. Median follow up was 43 months
(IQR 10.7-141.5, range 2–306). Patients included were 34
males and 26 females, with a mean age of 43.6 years (range
8–75). Forty-six (77%) patients were from Italy, of whom
28% were from the endemic region of Sicily; the remaining
14 (23%) patients were immigrants, mainly from North
Africa and Eastern Europe. The most frequent hepatic loca-
tion was the VII segment(19 cysts, 31%). Seventeen (28%)
patients had also hepatic inactive cysts (CE4 and CE5) in
addition to the CE3b considered for the analysis. Only
one patient harbored two CE3b cysts. Size at diagnosis
was available for 50 CE3b cysts: S =7 (14%); M = 29
(58%); L = 14 (28%).
Patients classification according to clinical manage-
ment is detailed in Figure 2. Median cumulative length
of ABZ intake was 12.2 months (IQR 4.2-38.3), while
median WW observational period was 48.8 months (IQR
30.8-116.9). Of the 17 patients who received ABZ through-
out the follow up, 7 reached stable inactivation, 1 became
inactive but relapsed once and then remained CE3b, and 9
remained unchanged. In this group, one of the patients
with a cyst that reached inactivation had been also treated
with PAIR while receiving ABZ. Of the 8 patients who re-
ceived WW only, none became spontaneously inactive. Of
the 35 patients who received periods of ABZ interspaced
by periods of ≥ 24 months WW, 3 reached stable inacti-
vation, 19 became inactive but relapsed (once n = 10,
twice n = 4, three times n = 4, four times n = 1) and 13
remained CE3b. In this group, of the patients who
reached stable inactivation, one had also been treated
with percutaneous drainage. Of the patients who re-
lapsed, one received PAIR, one received PAIR followed
by surgery, and one underwent radiofrequency thermal
ablation during the observation period [25]. Of the pa-
tients who remained CE3b, one also underwent PAIR
and one was surgically treated. Median time to inactiva-
tion and time to relapse are shown in Table 1.
The univariate and multivariate analysis showed that
ABZ treatment was positively associated with inactiva-
tion (hr 5.50, CI 2.61-11.60, p < 0.001, univariate analysis;
hr 7.18, CI 2.66-19.40, p = 0.001, multivariate analysis),
while Italian origin was negatively associated with inacti-
vation (hr 0.26, CI 0.09-0.76, p = 0.01, univariate analysis;
hr 0.29, CI 0.08-0.96, p = 0.04, multivariate analysis). None
of the variables analyzed were associated with relapse. The
influence of ABZ treatment and WW approach on inacti-
vation and relapse are depicted in Kaplan-Meier survival
plots (Figure 3). Significantly more cysts reached inacti-
vation during ABZ intake and in a shorter time than
during WW periods. Additionally, no difference was
found in rate and time to relapse between cysts during
ABZ or WW periods.
Multiple complications were experienced by 6 patients,
while 8 patients had a single occurrence of a complication.
The most common complication was abdominal pain
Table 1 Evolution of cysts according to treatment approach over time









Months of ABZ Months of WW
Inactivation 7 4 (4–9.5) 6 (3.75-7.25) 3 8 (7.5-9.5) 6 (4–7.5) 30 (25–39)
Relapse 1 6 9 3 19 8 (5–30.5) 8 (6–13) 22 (9.5-34.5) 143 (78–192)
Unchanged 9 5 (3.5-7) 13 10 (4–20) 62 (39–107)
*Time in months is expressed as median (IQR).
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(6 patients, 12 episodes), followed by rupture into the biliary
tree with jaundice or compression of biliary vessels (4 pa-
tients, 7 episodes). Other complications were allergic reac-
tions (4 cases with 2 reporting rash and 2 anaphylactic
shock episodes, of difficult interpretation and without
available documentation), cyst rupture (2 cases), bacterial
infection of the cyst (1 case), and increased liver enzymes
(2 cases) and anaemia (1 case) while on ABZ.
While on ABZ, the incidence of mild events was 0.0530
(IC 0.0194–0.1154) events per year and that of severe
events was 0.0176 (CI 0.0021-0.0638) events per year.
While on WW, the incidence of mild events was 0.0403
(CI 0.0193-0.0741) per year and that of severe events was
0.0403 (CI 0.0193-0.0741) per year as well. No statistically
significant differences were found in the incidence of ad-
verse events between the two treatment groups.
Of the 60 patients included in the study, 24 (40%) did
not have a consultation during the last two years of the
studied period (i.e. in 2011 and 2012) or longer. Of these,
11 (46%) could not be reached at the telephone number
provided at the time of the visit. Of the 13 patients (54%)
who could provide information, 4 (31%) returned for a
visit in late 2013: one patient was diagnosed with a relapse
seven years after the last visit, one remained a stable CE5,
and two remained CE3b three years after the last visit. Of
the 9 patients who were only interviewed by telephone
(69%), one underwent surgery in another hospital as he
wanted the cyst removed and was not evaluated further
since then, one patient died for reasons unrelated to CE,
two patients declared to be followed in another hospital
closer to their residence, and all other patients did not
seek further medical advice because they declared to be
asymptomatic and deemed further visits unnecessary.
Discussion
To our knowledge, this is the first study on this subject
in the literature, although with the limitations of a
retrospective study on relatively small numbers of sub-
jects. However, these figures are not negligible when tak-
ing into account that CE is a neglected disease with low
prevalence and extremely heterogeneous clinical presen-
tation and management practices, and our results come
from a single referral centre experience. Taken together,
they provide initial evidence on the feasibility of a WW
approach to CE3b cysts in selected circumstances.
The introduction of the WHO-IWGE classification of
echinococcal cysts, followed by the expert consensus for
CE diagnosis and treatment, has provided a long needed
framework for the clinical management of this condi-
tion [4,6]. Nevertheless, the current management of CE
is still largely based on expert opinion and moderate to
poor evidence [4]. Four treatment modalities are cur-
rently available for CE (surgery, percutaneous treat-
ments, medical therapy with benzimidazole derivatives
such as albendazole, and a watch and wait approach).
However, longitudinal controlled studies comparing the
efficacy and effectiveness of the different treatment op-
tions for specific clinical stage are lacking. As a conse-
quence, the issue of “best” treatment for echinococcal
cysts of the liver is still controversial [4].
CE3b cysts are the least responsive to non-surgical
treatments and relapse almost invariably occurs soon
after ABZ discontinuation [11,19]. However, in our experi-
ence they often show an indolent behavior with infrequent
development of complications and as such they are often
assigned to a “watch-and-wait” approach when a surgical
intervention does not appear to be necessary and the pa-
tient agrees to comply with a regular follow-up. We ana-
lyzed treatment outcome and incidence of complications
in patients with hepatic CE3b cysts managed with either
albendazole or watch-and-wait approach to evaluate their
effectiveness and safety.
Our results show that during ABZ treatment cysts
showed a higher probability to become inactive and
Figure 3 Kaplan Meier survival curve of inactivation and relapse.
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inactivation occurred in a shorter time period compared
to periods during which cysts were managed expect-
antly. In addition, the probability of and time to relapse
after initial ABZ-induced inactivation did not signifi-
cantly differ during ABZ or WW periods. This is un-
likely to be related to any percutaneous interventions
also performed in some patients, as the final outcome of
the 5 patients who received this treatment was indeed
stable inactivation in only 1 case. These results indicate
that treatment with ABZ does not induce permanent in-
activation of CE3b cysts, at least not in our cohort.
While temporary response to ABZ treatment was pre-
dictable, the correlation between outcome and geograph-
ical origin of patients is difficult to explain. This different
behaviour is likely not due to the presence of different CE
genetic strains in different areas as recent investigations
have shown that the G1-G3 E. granulosus sensu stricto
genotype complex is largely prevalent in all endemic areas
[26-31]. Cyst size was unrelated to treatment outcome, in
contrast with what reported by Stojkovic et al. [32].
We found no statistically significant difference in the
rate of complications during ABZ or WW. Thus, the de-
cision not to treat uncomplicated CE3b cysts does not
seem to have an increased risk of a mild or severe adverse
event in our series, at least over a median observation
period without treatment of 48.8 months. One of the two
patients who reported an (undocumented) anaphylactic re-
action during WW was receiving amoxicillin-clavulanate at
that time, a drug that might have caused this event [33]. As
for the second patient reporting an episode of shock, this
occurred before she presented to our clinic. Because we
never witnessed the event, the actual occurrence of a true
anaphylactic shock should be taken cautiously.
Surgery was performed on 3 patients during WW
period, due to rupture into the biliary tree (n = 2) and
cyst infection (n = 1). However, we observed rupture into
the biliary tree with jaundice also during ABZ intake pe-
riods, although this did not result in the decision to refer
the patient to surgery due to patient-related issues.
Taken together, our results suggest that a WW ap-
proach to CE3b cysts is feasible. Nevertheless, one
should be cautious in drawing conclusions on the applic-
ability of WW for all patients with CE3b cysts. The loss
of CE patients to follow-up is a problem commonly
faced by clinicians. In our series, of those patients who
did not have a consultation during the last two years of
the studied period (i.e. in 2011 and 2012) or longer and
could be reached by telephone, 38% declared that they
did not seek further medical advice because they were
asymptomatic and they did not consider a control visit
necessary. However, it is extremely important to stress
that a constant, long-term follow-up of patients with
CE3b cysts is mandatory when surgery is not considered
the first choice based on a patient-tailored approach,
and clearly, a good doctor-patient relationship and a bet-
ter explanation of the necessity of regular follow-up of
even asymptomatic CE cysts should be offered. Indeed,
major complications such as rupture into the biliary tree
may develop during both WW and ABZ treatment pe-
riods, therefore non-surgical approaches, including WW,
should be considered only for those patients who adhere
strictly to the follow-up schedule.
Conclusions
In conclusion, our study shows that ABZ treatment does
induce inactivation of CE3b cysts, but this is only tempor-
ary. Additionally, during WW, CE3b cysts remain stable
over time. As the rate of adverse events during ABZ treat-
ment and WW observation did not differ significantly,
expectant management might represent a viable option
for patients with asymptomatic CE3b cysts that do not
warrant surgery and who can comply with regular follow-
up. In the majority of cases, patients with CE3b cysts have
been receiving treatment(s) with ABZ interrupted by
observation periods without treatment. Therefore, a dir-
ect comparison between those only treated with ABZ
and those only untreated was not possible. Longer pro-
spective observation of a larger cohort after allocation
to clearly distinct management options is needed to
confirm our findings.
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